The GLP-1 wars are heating up. After telehealth brand Hims & Hers aired its first Super Bowl commercial Sunday night, competitor Novo Nordisk, which makes competing weight loss drugs Ozempic and Wegovy, responded with its own print ads on Monday morning.
“Do you really know what you’re injecting in your body?” reads text in the print ad, above a needle and vial labeled compounded semaglutide. “Bottom line: If the label doesn’t say Wegovy® (semaglutide) or Ozempic® (semaglutide), it’s not FDA approved and you have no idea what’s inside,” the text continues.
The ad ran in the New York Times and USA Today, said a spokeswoman for the Danish pharmaceutical giant.